A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: A case report

Takaya Takeuchi | Yunosuke Matsuura | Yoshimasa Yamamura | Momoko Ohkusu | Shohei Koyama | Takeshi Kawaguchi | Mayumi Akai Nagayasu | Hiroyuki Komatsu | Akihiko Okayama | Tetsunori Ishikawa | Tatsuya Atsumi | Kazuo Kitamura

1Department of Internal Medicine, Circulatory and Body Fluid Regulation, University of Miyazaki, Miyazaki, Japan
2Center for Post-Graduation Clinical Training, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
3Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan
4Clinical Laboratory, University of Miyazaki Hospital, Miyazaki, Japan
5Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
6Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Correspondence
Yunosuke Matsuura, Department of Internal Medicine, Circulatory and Body Fluid Regulation, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan.
Email: yunosuke_matsuura@med.miyazaki-u.ac.jp

Abstract
Patients with immune thrombocytopenia have increased risks of bleeding and thrombosis. The acute-phase treatment for venous thromboembolism complicated with severe immune thrombocytopenia involves a “platelet dilemma” in therapeutic decision-making.

KEYWORDS
anti-thrombotic therapy, immune thrombocytopenia, venous thromboembolism

1 | INTRODUCTION

Immune thrombocytopenia is associated with increased risks of bleeding and thrombosis. The treatment for venous thromboembolism complicated with severe thrombocytopenia involves a “platelet dilemma” in therapeutic decision-making. Thrombotic exacerbation should be considered when increasing the platelet count to initiate anti-coagulation therapy in cases that involve immune thrombocytopenia.

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by an increased risk of bleeding. Furthermore, recent reports have described a paradoxically increased incidence of arterial and venous thromboembolic events in patients with ITP compared with that in patients without ITP. Thus, a lower platelet count in cases of ITP does not prevent thrombotic complications.

The co-existence of thrombotic and bleeding risks, which is frequently observed in cases of cancer-associated thrombosis, creates a therapeutic dilemma regarding the trade-offs that are needed to manage their risks. Patients with ITP are similarly exposed to both risks, although the underlying mechanism is different from that in cancer cases. It would be useful to establish therapeutic
guidelines for managing ITP-associated thrombosis; however, guideline development is complicated by the complex and heterogeneous clinical background of ITP-associated thrombosis. Therefore, the accumulation of longitudinal case information is needed to better understand the clinical scenarios wherein thrombotic complications are encountered in ITP cases. We report a case involving severe ITP with venous thromboembolism (VTE) and discuss the clinical dilemma regarding managing the risks of ITP-associated thrombosis and its related treatments.

2 | CASE REPORT

A 51-year-old woman was referred to our hospital because of sudden-onset right leg edema and dyspnea. At admission, her blood pressure was 120/70 mmHg, heart rate was 70/min, and oxygen saturation was 98% (2 L/min oxygen supply via a nasal cannula). Despite the vital signs implying a relatively stable hemodynamic profile, we observed bleeding signs that included purpura in the lower extremities, epistaxis, and petechiae of the hard palate. The patient's medical records revealed a history of smoking and diagnosis of ITP, with splenectomy performed when she was a teenager. Following over 20-year disease-free period after splenectomy, the patient experienced ITP relapse and was subsequently diagnosed with mixed connective tissue disease (MCTD). The patient had subsequently been treated for secondary ITP using 20 mg/day of oral prednisolone (PSL).

Echocardiography performed at admission revealed mild pulmonary hypertension (tricuspid regurgitation pressure gradient: 39 mmHg, Figure 1A) without a D-shaped left ventricle (Figure 1B). In addition, an ultrasonography (US) examination for deep vein thrombosis (DVT) revealed low-echoic and partially floating thrombi (Figure 1C) in the proximal femoral vein. Contrast-enhanced computed tomography (CT) revealed obvious thromboembolism in the bilateral pulmonary arteries (Figure 1D) and thrombi extending from proximal to distal in the femoral vein (Figure 1E). Based on these signs, the patient was diagnosed with hemodynamically stable pulmonary thromboembolism (PTE) and fresh proximal DVT, which required anti-coagulation treatment.

At admission, the blood test revealed highly severe thrombocytopenia (5 × 10^3/μl), which suggested that immediate initiation of anti-coagulation treatment for VTE was inadvisable based on the risk of fatal bleeding. Thus,

**FIGURE 1** Findings from echocardiography, lower extremity ultrasonography, and computed tomography regarding venous thromboembolism. Echocardiography shows a mildly increased tricuspid regurgitation peak gradient (A) and no evidence of a D-shaped left ventricle in the short axis view (B). RV: right ventricle. (C): Lower extremity ultrasonography reveals a partially floating thrombus (red arrow) with low-to-isometric echogenicity in the proximal femoral vein. FA: femoral artery, FV: femoral vein. (D, E): Contrast-enhanced computed tomography reveals bilateral pulmonary artery embolic thrombi (red arrows, D) and deep vein thrombosis extending from proximal to distal in the right femoral vein.
a temporary inferior vena cava (IVC) filter was placed after a platelet transfusion. In addition, the PSL dose was increased to 1 mg/kg to avoid bleeding. Figure 2 shows the therapeutic regimen and changes in platelet counts and D-dimer concentrations during the treatment for acute VTE until a negative D-dimer result was observed (<1.0 µg/ml).

The platelet counts responded to the increased PSL dose; however, the right lower extremity edema worsened (vs. at admission), and blood tests revealed a dramatically increased D-dimer concentration (44 µg/ml). Follow-up using US and CT confirmed that DVT apparently worsened in the right lower extremity; however, thrombi in the pulmonary arteries remained unchanged, and no evidence of thrombus-induced filter occlusion was observed. The platelet count reached $5 \times 10^4/\mu L$ on day 7, and anti-coagulation treatment was initiated using unfractionated heparin, which was subsequently changed to warfarin therapy to achieve a prothrombin time/international normalized ratio of 2.0. The D-dimer concentrations rapidly decreased in response to the anti-coagulation treatment, and we confirmed a negative D-dimer result on day 27. On day 35, the CT images revealed no large thrombi in the deep leg veins and pulmonary arteries, and the IVC filter was finally removed on day 42. The patient did not experience any worsening of bleeding signs during the clinical course.

During the treatment course, we also investigated the underlying risk of thrombosis. Table 1 shows the results of blood tests, which included factors and autoantibodies associated with coagulation disorders, connective tissue diseases, and anti-phospholipid syndrome. The clinical manifestations and blood test results at admission indicated that the concomitant autoimmune disease was systemic lupus erythematosus (SLE) rather than MCTD. Although anemia subsequent to the thrombocytopenia was also present, no evidence of hemolysis was observed. In addition, anti-cardiolipin antibodies were detected at a low titer; however, we did not detect anti-cardiolipin-β2-glycoprotein I antibodies, lupus anticoagulants, or a prolonged activated partial thromboplastin time. Therefore, the laboratory data and clinical manifestations, including pregnancy history, did not satisfy the diagnostic criteria for anti-phospholipid syndrome. In addition, weakly positive results were observed for the immunoglobulin (IG) M subtype of anti-phosphatidylerine/prothrombin antibodies. Bone marrow aspiration revealed normal to mildly hypercellular marrow and an increase in mature megakaryocyte count, which did not contradict the diagnosis of ITP or provide any evidence of malignancy.

### 3 | DISCUSSION

Our patient developed VTE even with severe thrombocytopenia and bleeding signs. Although this pathological scenario is seemingly paradoxical, multiple recent studies have demonstrated that patients with ITP have an increased risk of thrombotic complications compared with those without ITP.1,2 In addition, ITP-related risk factors for developing thrombotic complications have been reported.4 Similarly, our case involved various risk factors for ITP-related thrombosis, including steroid use,5,6 a history of smoking,7 positive anti-phospholipid antibodies,8-10 comorbid SLE,1 and a history of splenectomy.11-13 However, even in ITP cases involving these risk factors, the magnitude of thrombotic risk that is needed to justify the initiation of preventative antithrombotic therapy remains unclear, especially given the trade-off regarding the increased risk of bleeding.14 Balitsky et al. proposed a simple risk assessment score that might be helpful for balancing the thrombotic and bleeding risks during anti-thrombotic therapy in ITP cases.15 In this case,
TAKEUCHI et al.

...score was initially negative, indicating a trend toward a high bleeding risk even when developing VTE. However, further studies are required to develop more personalized strategies for patients with ITP.

The present case involved an intriguing clinical course in terms of immunological comorbidity. Prior medical records before admission to our hospital showed that the initial diagnosis was primary ITP (previously described as idiopathic thrombocytopenia); however, SLE was confirmed as a comorbidity at this admission. A recent population-based study revealed that patients with primary ITP have an approximately 27-fold increased risk of developing SLE, and another previous report revealed that 12% of patients with SLE were initially diagnosed with primary ITP. Thus, careful monitoring is needed to identify comorbid SLE, even after a diagnosis of primary ITP, as therapeutic options for SLE might be effective in cases with intractable ITP, and these treatments might make it possible to avoid splenectomy. Furthermore, newly emerged comorbidities after the diagnosis of ITP may alter the risk stratification of thrombotic complications. Therefore, using only a single diagnosis or risk stratification point may complicate the risk estimation for developing ITP-associated thrombotic complications, and follow-up assessments may be needed for effective thrombotic risk modeling.

**TABLE 1** Laboratory data at admission

| Peripheral blood | Biochemistry | Immunological test |
|------------------|--------------|-------------------|
| WBC (×10³/µl)   | TP (g/dl)    | ANA (fold)        |
| 8.3 (3.3–8.6)   | 6.84 (6.6–8.1) | 1280 (<40)        |
| Neutrophil (%)  | Albumin (g/dl) | C3 (mg/dl)       |
| 85.4 (37–72)    | 2.36 (4.1–5.1)    | 58 (73–138)       |
| Lymphocyte (%)  | T-bil (mg/dl)  | C4 (mg/dl)        |
| 13.6 (20–50)    | 0.3 (0.4–1.5)      | 4 (11–31)         |
| Monocyte (%)    | D-bil (mg/dl)  | CH 50 (/ml)       |
| 0.8 (4.1–10.6)  | 0.1 (0.05–0.3)     | 14 (28–55)        |
| Eosinophil (%)  | AST (U/L)      | Anti-SSA ab (U/ml)|
| 0 (0.6–8.3)     | 28 (13–30)        | 155 (<10)         |
| Basophil (%)    | ALT (U/L)      | Anti-SSB ab (U/ml)|
| 0.2 (0–1.3)     | 14 (7–23)         | <1 (<10)          |
| RBC (×10⁹/µl)   | LD (U/L)       | Anti-Sm ab (U/ml) |
| 3.14 (3.86–4.92)| 289 (124–222)   | 2 (<7)            |
| Hemoglobin (g/dl)| CK (U/L) | Anti-dsDNA IgG ab (IU/ml) |
| 8.4 (11.6–14.8)| 69 (41–153)    | 19 (<12)          |
| Hematocrit (%)  | BUN (mg/dl)    | Anti-RNP ab (U/ml)|
| 26.4 (35.1–44.4)| 13.4 (8–20)   | 2.1 (<10)         |
| MCV (FL)        | Cre (mg/dl)    | Anti-CLβ2GPI ab  |
| 84.1 (83.6–98.2)| 0.56 (0.46–0.79)| <1.2 (<3.5)       |
| MCHC (g/dl)     | Na (mmol/L)    | Anti-PS-PT IgM (U) |
| 31.8 (31.7–35.3)| 136 (138–145) | 42.9 (<30)        |
| Reticulocyte (%)| K (mmol/L)     | Anti-PS-PT IgG (U) |
| 3.1 (0.8–2.2)   | 3.6 (3.6–4.8)  | 18.6 (<30)        |
| Platelet (×10³/µl)| Cl (mmol/L) | Lupus Anticoagulant |
| 5 (158–348)    | 107 (101–108) | 1.17 (<1.3)       |
| Coagulation     | BNP (pg/ml)    | (Before/after, sec)|
| PT (sec)        | 8.77 (<18.4)  | 42.7/36.4         |
| 12.1 (10.5–12.5)| (16–12–60) | (46–100)         |
| PT-INR          | Ferritin (ng/ml)| Anti-cardiolipin IgM ab |
| 1.12            | 16 (12–60)     | 15 (<8)           |
| APTT (sec)      | UIBC (µg/dl)   | Anti-cardiolipin IgG ab |
| 29.6 (25–35)   | 261 (137–325) | 20 (<10)         |
| FDP (µg/ml)     | TIBC (µg/dl)  | Helicobacter pylori ab |
| 25.6 (<5)      | 279 (236–406) | <3 (<10)         |
| AT-III (%)      | Fe (µg/dl)     | (18–40–188)       |
| 88 (80–130)    | Arterial blood gas analysis (2 L/min O2 supply) |
| pH              | 7.49 (7.35–7.45)|                 |
| D-dimer (µg/ml)| pCO2 (mmHg) | 31.3 (27–39)      |
| 8.31 (0–1)     | 100 (83–108)  |                 |
| Protein S activity (%) | pO2 (mmHg) | 100 (83–108)  |
| 40 (60–150) | 23.6 (21.2–28.3) |
| Protein C activity (%) | BE (mmol/L) | 0.9 (2–3)      |
| 75 (54–146)    | 52              |                 |
| ADAMTS13 activity (%) | BE (mmol/L) | 0.9 (2–3)      |

**Abbreviations:** ADAMTS13, A Disintegrin-like and Metalloproteinase with Thrombospondin type 1 motifs 13; ALT, Alanine aminotransferase; ANA, Antinuclear Antibody; APTT, Activated Partial Thromboplastin Time; AST, Aspartate aminotransferase; AT-III, Antithrombin-III; T-bil, Total bilirubin; BE, Base Excess; BNP, Brain natriuretic peptide ab antibody; BUN, Blood urea nitrogen; CK, Creatinine Kinase; CLβ2GPI, Cardiolipin-β2-Glycoprotein I; Cre, Creatinine; CRP, C-reactive protein; D-bil, Direct bilirubin; dsDNA, double-stranded Deoxyribonucleic Acid; FDP, Fibrinogen Degradation Products; LD, Lactate Dehydrogenase; MCHC, Mean Corpuscular Hemoglobin Concentration; MCV, Mean Corpuscular Volume; PA-IgG, Platelet-Associated Immunoglobulin G; PS-PT, Phosphatidylserine Prothrombin; PT, Prothrombin Time; PT-INR Prothrombin Time-International Normalized Ratio; RBC, Red Blood Cell; RNP, Ribonucleoprotein; TIBC, Total iron binding capacity; TP, Total protein; UIBC, Unsaturated iron binding capacity; WBC, White Blood Cell.
There are no guidelines for managing thrombotic complications in patients with ITP, which may be related to their heterogeneous clinical background. Some experts recommend a platelet cutoff of ≥50,000/µl to start anti-coagulation treatment for thrombotic complications,\(^\text{14,18}\) and we used this cutoff value to guide the initiation of anti-coagulation therapy. The currently available options for increasing platelet count include steroid treatment, IG therapy, and thrombopoietin receptor agonist treatment. In the present case, steroid treatment and IG therapy were options for increasing the platelet count; however, we selected PSL administration at an increased dose because the patient had a relatively stable hemodynamic profile, and PTE recurrence could at least be partially prevented using the IVC filter. Another option is IG therapy, which takes 1–2 days to increase platelet count.\(^\text{19}\) Thus, IG therapy might be preferable over steroid treatment in patients with VTE showing signs of hemodynamic collapse, given the unavoidable use of anti-coagulation treatment during acute-phase intensive treatment that includes circulatory support or surgery. Nevertheless, a rapid short-term increase in the platelet count might also be associated with adverse effects, including fatal thrombotic complications.\(^\text{20}\) Thus, thrombogenic responses could reasonably be expected during treatment to increase platelet count using IG therapy\(^\text{21}\) or steroid treatment.\(^\text{22}\) Additionally, our patient exhibited thrombotic exacerbation in the right lower extremity with a markedly elevated D-dimer concentration during the period when the platelet counts responded to the increased PSL dose. Although there is no clearly appropriate strategy for managing this type of thrombotic exacerbation, an IVC filter might be useful to avoid fatal PTE. The acute-phase management of thrombotic complications in severe thrombocytopenia is extremely challenging because of this therapeutic dilemma. However, we hope that this report will provide information regarding how to manage the trade-off between increasing platelet counts and avoiding sudden fatal thrombotic exacerbation. In addition, we are presently in the era of artificial intelligence (AI), wherein longitudinal complex clinical information could be integrated. In a case of ITP associated with thrombotic complications, if we precisely accumulate the clinical data in combination with AI use, it will be possible to establish a more personalized risk scoring system to safely manage cases of dilemma.

In conclusion, the acute-phase treatment for VTE complicated by severe thrombocytopenia involves a “platelet dilemma” in terms of therapeutic decision-making. Thrombotic exacerbation is an ITP-specific clinical scenario that should be considered when increasing platelet counts to initiate anti-coagulation therapy.

**CONFLICTS OF INTEREST**
None declared.

**AUTHOR CONTRIBUTIONS**
TT, MO, and YM collected the data and drafted the manuscript. TT, MO, YY, YM, SK, TI, and TK managed the patient. MAN performed the histological examination. HK, AO, TI, TA, and KK supervised the manuscript.

**ETHICAL APPROVAL**
An ethical review is not required for this type of article. Written informed consent for the publication of this article was obtained from the patient.

**CONSENT**
Published with written consent of the patient.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available from the corresponding author upon the reasonable request.

**ORCID**
Yunosuke Matsuura ORCID ID: https://orcid.org/0000-0003-2927-7284

**REFERENCES**
1. Machin N, Ragni MV, Comer DM, Yabes JG. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: an NIS study. *Thromb Res.* 2018;172:80-85.
2. Cines DB, Bussel JB, Lieberman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. *Blood.* 2009;113(26):6511-6521.
3. Langeberg WJ, Schoonen WM, Eisen M, Gamelin L, Stryker S. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. *Int J Hematol.* 2016;103(6):655-664.
4. Takagi S, Suzuki I, Watanabe S. Risk of thromboembolism in patients with immune thrombocytopenia. *J Hematol Thrombo Dis.* 2015;3:185.
5. Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. *J Thromb Haemost.* 2014;12(8):1266-1273.
6. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. *JAMA Intern Med.* 2013;173(9):743-752.
7. Ito S, Fujiwara SI, Ikeda T, et al. Evaluation of thrombotic events in patients with immune thrombocytopenia. *Ann Hematol.* 2020;99(1):49-55.
8. Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. *Br J Haematol.* 2013;161(5):706-714.
9. Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. *Thromb Res.* 2012;130(suppl 1):S37-S40.
10. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with
or without antiphospholipid antibodies. *Arthritis Rheum*. 2009;61(1):29-36.

11. Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. *Eur J Haematol*. 2016;97(4):321-330.

12. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sørensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. *J Thromb Haemost*. 2010;8(6):1413-1416.

13. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. *Blood*. 2013;121(23):4782-4790.

14. Matzdorff A, Beer JH. Immune thrombocytopenia patients requiring anticoagulation—maneuvering between Scylla and Charybdis. *Semin Hematol*. 2013;50(suppl 1):S83-S88.

15. Balitsky AK, Kelton JG, Arnold DM. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. *Blood*. 2018;132(25):2684-2686.

16. Zhu FX, Huang JY, Ye Z, Wen QQ, Wei JC. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. *Ann Rheum Dis*. 2020;79(6):793-799.

17. Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. *J Rheumatol*. 1997;24(5):867-870.

18. Pishko AM, Misgav M, Cuker A, et al. Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists. *J Thromb Thrombolysis*. 2018;46(1):24-30.

19. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. *Am J Hematol*. 2008;83(2):122-125.

20. Rungjirajittranon T, Owattanapanich W. A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report. *J Med Case Rep*. 2019;13(1):25.

21. Ramírez E, Romero-Garrido JA, López-Granados E, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. *Thromb Res*. 2014;133(6):1045-1051.

22. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. *Thromb Res*. 2006;118(2):247-252.

**How to cite this article:** Takeuchi T, Matsuura Y, Yamamura Y, et al. A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: A case report. *Clin Case Rep*. 2021;9:e04805. [https://doi.org/10.1002/ccr3.4805](https://doi.org/10.1002/ccr3.4805)